Cochrane · intervention · CD013627
Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID‐19 infection to improve patient outcomes and to protect healthcare workers treating them
Burton, MJ, Clarkson, JE, Goulao, B, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Full textEvery question was extracted from the full review (methods and results), not only its Summary of Findings table.
Questions
7
current version
GRADE rated
0
No studies
7
Included studies
0
as reported
No studies 7 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Patients with suspected or confirmed COVID-19 infection (any healthcare setting) | No included studies |
| Intervention | Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, frequency or dosage | No included studies |
| Comparison | No treatment; Saline; Water | No included studies |
| Outcomes | Mortality (RECOVERY); Hospitalisation status (RECOVERY); Use of ventilation (RECOVERY); Use of renal dialysis or haemofiltration (RECOVERY); Incidence of symptomatic or test-positive COVID-19 infection in HCWs; Anosmia (or disturbance in sense of smell); Change in COVID-19 viral load in patients; COVID-19 viral content of aerosol; Changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx; Other adverse events (allergy, irritation/burning of mucosa, long-term staining, accidental ingestion) | No included studies |
| Study designs | Randomised controlled trials; quasi-RCTs; non-randomised controlled trials; prospective cohort studies; retrospective cohort studies; cross-sectional studies; controlled before-and-after studies | No included studies; 16 ongoing studies identified (14 RCTs, 1 before-and-after study, 1 non-randomised study), aiming to enrol nearly 1250 participants |
| Timing | Primary outcomes assessed at a minimum of 2 weeks; no minimum follow-up for other outcomes; no minimum study duration | No included studies |
Search date: 2020-06. Databases: Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; WHO COVID-19 Global literature on coronavirus disease; Cochrane COVID-19 Study Register
Questions and results
Antimicrobial mouthwash and/or nasal spray (alone or in combination), any concentration, frequency or dosage vs No treatment, saline, or water
Population: Patients with suspected or confirmed COVID-19 infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of symptomatic or test-positive COVID-19 infection in healthcare workers Minimum 2 weeks | No data available (no included studies) | 0 studies | No studies |
COVID-19 viral content of aerosol (when present) | No data available (no included studies) | 0 studies | No studies |
Anosmia (or disturbance in sense of smell) Minimum 2 weeks | No data available (no included studies) | 0 studies | No studies |
Other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) | No data available (no included studies) | 0 studies | No studies |
Change in COVID-19 viral load in patients | No data available (no included studies) | 0 studies | No studies |
RECOVERY trial outcomes (mortality; hospitalisation status; use of ventilation; use of renal dialysis or haemofiltration) Minimum 2 weeks | No data available (no included studies) | 0 studies | No studies |
Changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx | No data available (no included studies) | 0 studies | No studies |